COVID-19 vaccines: ethical framework concerning human challenge studies.

Daniela Calina, Thomas Hartung, Anca Oana Docea, Demetrios A Spandidos, Alex M Egorov, Michael I Shtilman, Felix Carvalho, Aristidis Tsatsakis
{"title":"COVID-19 vaccines: ethical framework concerning human challenge studies.","authors":"Daniela Calina,&nbsp;Thomas Hartung,&nbsp;Anca Oana Docea,&nbsp;Demetrios A Spandidos,&nbsp;Alex M Egorov,&nbsp;Michael I Shtilman,&nbsp;Felix Carvalho,&nbsp;Aristidis Tsatsakis","doi":"10.1007/s40199-020-00371-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The pandemic associated with the new SARS-CoV-2 coronavirus continues to spread worldwide. The most favorable epidemic control scenario, which provides long-term protection against COVID-19 outbreak, is the development and distribution of an effective and safe vaccine. The need to develop a new COVID-19 vaccine is pressing; however, it is likely to take a long time, possibly several years. This is due to the time required to demonstrate the safety and efficacy of the proposed vaccine. and the time required to manufacture and distribute millions of doses.</p><p><strong>Objectives: </strong>To accelerate this development and associated safety testing, the deliberate infection of healthy volunteers has been suggested. The purpose of this short communication is to describe the ethical aspects of this type of testing, RESULTS: Deliberate infection of volunteers with a dangerous virus such as SARS-CoV-2 was initially considered unethical by researchers; but the current pandemic is so different from previous ones that these studies are considered ethical if certain criteria are met. Participants in human challenge studies must be relatively young, in good health and must receive the highest quality medical care, with frequent monitoring. Tests should also be performed with great caution and specialized medical supervision. Besides, the fact that obtaining vaccines faster through deliberate infection studies of healthy people has greater benefits than risks, has been demonstrated by obtaining other vaccines in other historical pandemics such as: smallpox, influenza, malaria, typhoid fever, Dengue fever and Zika.</p><p><strong>Conclusions: </strong>One possibility to shorten the time required for the development of COVID-19 vaccines is to reduce clinical phases II and III by using human challenge studies through eliberate infection of healthy volunteers with SARS-CoV-2 after administration of the candidate vaccine. Accelerating the development of a COVID-19 vaccine even for a few weeks or months would have a great beneficial impact on public health by saving many lives.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"28 2","pages":"807-812"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40199-020-00371-8","citationCount":"49","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40199-020-00371-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/8/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 49

Abstract

Background: The pandemic associated with the new SARS-CoV-2 coronavirus continues to spread worldwide. The most favorable epidemic control scenario, which provides long-term protection against COVID-19 outbreak, is the development and distribution of an effective and safe vaccine. The need to develop a new COVID-19 vaccine is pressing; however, it is likely to take a long time, possibly several years. This is due to the time required to demonstrate the safety and efficacy of the proposed vaccine. and the time required to manufacture and distribute millions of doses.

Objectives: To accelerate this development and associated safety testing, the deliberate infection of healthy volunteers has been suggested. The purpose of this short communication is to describe the ethical aspects of this type of testing, RESULTS: Deliberate infection of volunteers with a dangerous virus such as SARS-CoV-2 was initially considered unethical by researchers; but the current pandemic is so different from previous ones that these studies are considered ethical if certain criteria are met. Participants in human challenge studies must be relatively young, in good health and must receive the highest quality medical care, with frequent monitoring. Tests should also be performed with great caution and specialized medical supervision. Besides, the fact that obtaining vaccines faster through deliberate infection studies of healthy people has greater benefits than risks, has been demonstrated by obtaining other vaccines in other historical pandemics such as: smallpox, influenza, malaria, typhoid fever, Dengue fever and Zika.

Conclusions: One possibility to shorten the time required for the development of COVID-19 vaccines is to reduce clinical phases II and III by using human challenge studies through eliberate infection of healthy volunteers with SARS-CoV-2 after administration of the candidate vaccine. Accelerating the development of a COVID-19 vaccine even for a few weeks or months would have a great beneficial impact on public health by saving many lives.

Abstract Image

Abstract Image

COVID-19疫苗:关于人体挑战研究的伦理框架。
背景:与新型SARS-CoV-2冠状病毒相关的大流行继续在全球传播。对COVID-19疫情提供长期保护的最有利的疫情控制情景是开发和分发有效安全的疫苗。开发新型COVID-19疫苗的需求十分迫切;然而,这可能需要很长时间,可能需要几年时间。这是由于需要时间来证明拟议疫苗的安全性和有效性。以及制造和分发数百万剂所需的时间。目的:为了加速该技术的发展和相关的安全性试验,建议在健康志愿者中进行故意感染。结果:研究人员最初认为,故意让志愿者感染SARS-CoV-2等危险病毒是不道德的;但目前的大流行与以前的大流行非常不同,如果满足某些标准,这些研究就被认为是道德的。人体挑战研究的参与者必须相对年轻,健康状况良好,必须接受最高质量的医疗护理,并经常进行监测。测试也应该在非常谨慎和专门的医疗监督下进行。此外,在天花、流感、疟疾、伤寒、登革热和寨卡病毒等其他历史上的大流行中,通过对健康人进行故意感染研究,更快地获得疫苗的好处大于风险,这一事实已得到证实。结论:缩短COVID-19疫苗开发所需时间的一种可能性是,通过使用候选疫苗后释放健康志愿者的SARS-CoV-2感染,进行人体挑战研究,减少临床II期和III期。加快开发COVID-19疫苗,即使是几周或几个月,也会通过挽救许多生命,对公共卫生产生巨大的有益影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信